[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610453":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":11,"armGroups":22,"interventions":33,"overallOfficials":38,"centralContacts":42,"locations":51,"responsibleParty":94,"collaborators":96,"id":99,"slug":11,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":11,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":11,"enrollmentInfo":107,"targetDuration":11,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":11,"overallStatus":116,"whyStopped":11,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"University of Minnesota","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Time to Death",null,"24 Weeks",{"measure":14,"description":15,"timeFrame":12},"Functional Status","Modified Rankin score",{"allocation":17,"interventionModel":18,"interventionModelDescription":11,"primaryPurpose":19,"observationalModel":11,"timePerspective":11,"maskingInfo":20},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":21,"maskingDescription":11,"whoMasked":11},"NONE",[23,29],{"label":24,"type":25,"description":26,"interventionNames":27},"BPaLMZ Regimen","EXPERIMENTAL","bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide (BPaLMZ)",[28],"Drug: BPaLMZ Regimen",{"label":30,"type":31,"description":32,"interventionNames":11},"Standard of Care Regimen","NO_INTERVENTION","rifampicin, isoniazid, pyrazinamide, ethambutol (RHZE) therapy",[34],{"type":35,"name":24,"description":36,"armGroupLabels":37,"otherNames":11},"DRUG","bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide",[24],[39],{"name":40,"affiliation":5,"role":41},"David Boulware, MD","PRINCIPAL_INVESTIGATOR",[43,47],{"name":40,"role":44,"phone":45,"phoneExt":11,"email":46},"CONTACT","612-624-9996","coat.trial@gmail.com",{"name":48,"role":44,"phone":49,"phoneExt":11,"email":50},"Darlisha Williams, MPH","612-624-0469","will1223@umn.edu",[52,67,81],{"facility":5,"status":11,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Minneapolis","Minnesota","55455","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-93.26384,44.97997,{"lat":62,"lon":61},[65],{"name":40,"role":44,"phone":45,"phoneExt":11,"email":66},"Coat.trial@gmail.com",{"facility":68,"status":11,"city":69,"state":11,"zip":11,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Infectious Diseases Institute","Kampala","Uganda","UG",{"type":59,"coordinates":73},[74,75],32.58219,0.31628,{"lat":75,"lon":74},[78],{"name":79,"role":44,"phone":11,"phoneExt":11,"email":80},"David Meya, MBChB, MMed, PhD","david.meya@idi.co.ug",{"facility":82,"status":11,"city":83,"state":11,"zip":11,"country":70,"countryCode":71,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Mbarara University of Science and Technology","Mbarara",{"type":59,"coordinates":85},[86,87],30.64851,-0.60467,{"lat":87,"lon":86},[90],{"name":91,"role":44,"phone":92,"phoneExt":11,"email":93},"Conrad Muzoora","256772547175","conradmuzoora@gmail.com",{"type":95,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[97],{"name":68,"class":98},"UNKNOWN","100610453",false,"NCT07227779","B-PaLMZ for TB Meningitis","A PHASE 2 NOVEL ANTIMICROBIAL COMBINATION THERAPY TO TREAT TUBERCULOUS MENINGITIS","Inclusion Criteria:\n\n* First Episode definite or probable TBM with physician intent to treat\n* Age ≥18 years\n* Provision of Informed Consent by participant or surrogate\n* Living with HIV\n* Weight \\> 35kg, estimate or measured\n\nExclusion Criteria:\n\n* Additional active and confirmed CNS infection\n* Known rifampicin-resistant TB\n* Allergy or contraindication to a study medicine\n* More than 5 doses of any TB therapy received within the previous 14 days\n* Presence of jaundice, known liver cirrhosis, elevated ALT or AST \\>3x ULN, or total bilirubin \\>2x ULN\n* Estimated Glomerular Filtration Rate \\\u003C30 ml\u002Fmin\u002F1.73m2\n* Significant cardiac comorbidity, heart failure, arrhythmia, or QTc \\>450 ms\n* Pregnancy or Breastfeeding\n* Cryptococcal antigen positivity in blood\n* Condition which makes participation not in the participant's best interest","ALL","18 Years",{"count":108,"type":109},240,"ESTIMATED","INTERVENTIONAL",[112],"PHASE2","This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.",[115],"Tuberculous Meningitis","NOT_YET_RECRUITING","2026-06-17",{"date":119,"type":120},"2026-06-22","ACTUAL",{"date":122,"type":109},"2026-07-20",{"date":124,"type":109},"2030-08-31",{"name":5,"class":6},3]